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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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WEDNESDAY, NOVE MBER 30, 2011

The Holy Grail of Huntington's disease research: the
gene-positive, drug trials, and treatments
Living in the gray zone between my genetic test for Huntington’s disease
and the inevitable but indefinite onset of this devastating brain disorder, I
frequently feel forgotten in the excited discussion about impending clinical
trials to test potential treatments.
HD researchers want to include people like me in trials, but haven’t yet
found a way to do so.
I am a victim in waiting, but without any of the noticeable, classic
symptoms that would qualify me for participation in a clinical trial.
Because so much of the effort against HD is geared to helping the affected
and the caregivers, I sometimes sense that we, the asymptomatic (or premanifest) gene-positive, have been relegated to second priority.
Emotional impact
I recognize that I am, for the time being, relatively fortunate, but the
situation of perceived neglect, although unintentional, impacts me
emotionally.
I wonder if symptomatic people feel jealous towards me – just as I have
occasionally reacted with a furious inner jealousy when I learn that
someone has tested negative. In other instances, I have briefly felt smug
when I’m around or am thinking about people with symptoms.
In yet other instances, I feel compassion – and even profound guilt. I tell
myself, “You have no right to worry! You’re not even sick! Your life hasn’t
even been affected by the disease!”
Mostly, I just feel lucky to function normally and to have the opportunity
to enjoy daily life.
But then I remember, “Yes, I have been affected by this disease. It took
Mom’s life at only age 68, and it has robbed me and my family of so many
dreams.”
I literally dreamt about my status last night as my mind worked on this
article: a team of HD medical specialists put me through a series of exams
to see whether symptoms had begun, and, as I awaited the results, I used a
large red marker to edit this text.
Not coincidentally, it’s time to set up my annual checkup at the
Huntington’s Disease Society of America’s Center of Excellence for Family
Services and Research at the University of California, San Diego.
So far, those checkups have not turned up any of HD’s classic, outwardly
noticeable symptoms.
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But I am hyper-conscious of the fact that HD affects the brain ten or more
years before those symptoms start. If an effective treatment isn’t found in
the next few years, I will be doomed to follow in my mother’s footsteps.
Unable to reach the finish line?
The feelings of vulnerability and abandonment are magnified when I
remember that no current or impending HD clinical trial includes
participation of those of us who are pre-manifest.
In short, everything is currently focused on stopping HD already in
progress. Nobody has yet developed a workable strategy for preventing the
onset of HD.
Along with the scientists I have interviewed over the years, I am confident
that a significant treatment or series of treatments will become available in
the next decade or so to ameliorate the symptoms. Of course, I also hope
for a “cure,” but scientists don’t use that term. They talk of controlling or
managing the disease, because, of course, the defective HD gene cannot be
removed from the body.
But I’m deeply worried that scientists will still take many more years
beyond that to discover treatments for people like me, treatments that can
stave off onset and/or minimize symptoms.
Ever since I tested positive in 1999, I have been racing against my own
interior genetic clock to avoid symptoms and support the HD movement.
But the probability that my symptoms will start in the next few years
leaves me with the sensation of the marathon runner who glimpses the
finish line but ultimately cannot reach it.
Participation in studies
For now, pre-manifest people can participate in research studies. Whereas
clinical trials aim specifically to test the safety, tolerability, and efficacy of
a drug, studies seek to provide further information about a disease and/or
strategies for treating it.
Studies can also include a test of safety and tolerability of a substance, as
exemplified in the PREQUEL study, an investigation of coenzyme Q-10
exclusively in a pre-manifest group of 90 individuals. PREQUEL also aims
to “assess the usefulness of certain markers of HD in the blood, which may
help measure the rate of the disease progression or effects of medication.”
Its coordinators aim to use it as precursor to a clinical trial of coenzyme Q10, an antioxidant produced in the brain and that has led to the
improvement of symptoms in HD mouse models.
Major studies involving pre-manifest people include PREDICT-HD,
COHORT, and the forthcoming Enroll-HD, a new, worldwide HD database
expected to start gathering information in early 2012. (Click here to read
my previous article on Enroll-HD). Enroll-HD is sponsored by the CHDI
Foundation, Inc., the so-called “cure Huntington’s disease initiative,” a
multi-million-dollar effort backed by a group of anonymous donors.
Through the above-mentioned Center of Excellence, I have participated in
a number of studies, including COHORT, MRI studies, research involving
HD and the sense of smell, and an experiment with instruments designed
to measure loss in mobility. (Click here and here to read more.) I have also
given blood and, for many years, participated in cognitive batteries and a
Dementia Rating Scale study. I also took part as the only pre-manifest
individual in the Huntington’s Disease Drug Works program’s "treatment
now" observational trial of supplements, a rare opportunity for someone in
my situation.
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A ‘long time’ to gene-positive trials
The federal Food and Drug Administration (FDA) will not permit premanifest people to participate in clinical trials until beneficial results have
first been demonstrated in symptomatic patients. The FDA also requires
that researchers come up with useful ways to measure benefits in the premanifest.
I became acutely aware of the challenges of designing a drug for the premanifest during a July 2009 interview with Dr. Frank Bennett, the senior
vice president for research at Isis Pharmaceuticals, Inc., in Carlsbad, CA.
Along with CHDI, Isis is planning a clinical trial of a revolutionary drug
that, if successful, would attack HD at its genetic roots and slow or perhaps
even stop the progression of the disease in the brain.
Dr. Bennett told me that although the clinical trial will focus only on
symptomatic patients, he was “optimistic” that a way could be found to
help the pre-manifest, too.
Exhilarated by the promise of a potential “cure,” I wrote several
enthusiastic articles about Isis.
But privately I also felt somewhat desperate, because, as Dr. Bennett
explained, finding a solution for the pre-manifest would take a “long time.”
“Identifying when to start treating those patients is going to be a little
tricky, as you might imagine, because you don’t want to do it too soon,” he
said. By the same token, Dr. Bennett added, waiting too long would miss
the opportunity to protect brain cells, which, once damaged, could not
recover. “This is not a short-term fix but it’s something that’s going to take
a large number of years to figure out how to optimally treat these patients.”
Other path-breaking clinical trials face similar hurdles. Alnylam
Pharmaceuticals, which is close to starting its own clinical trial for a
similar attack on the disease’s genetic causes, plans to inject its drug
directly into the heads of patients, but they must first undergo an
operation so that a very fine needle can be inserted into their brains (click
here to read more). Medically, scientifically, and ethically speaking, only
symptomatic patients can undergo the many risks of such a trial.
As Dr. Bennett and others have noted, the FDA will display great caution
with these new kinds of drugs as well as the highly invasive delivery
systems. Isis and Alnylam are striving to minimize levels of risk and
invasiveness.
Seeking the Holy Grail
HD researchers face a major challenge in finding a treatment for the premanifest. It’s really the Holy Grail not only for HD, but also for other
neurological diseases such as Alzheimer’s in which brain damage occurs
many years before symptoms appear. Ideally, researchers want to design
medications that will completely prevent these diseases.
In a recent e-mail to me, CHDI President Robi Blumenstein elaborated on
this point with an analogy.
“The purpose of a cholesterol-lowering drug is to prevent heart disease,
not lower cholesterol for its own sake,” he explained. “Cholesterol-lowering
drugs were tested on people at risk for heart disease. By analogy, we would
like to test HD drugs on gene-positive people (like you) at risk of
developing symptoms of HD to see if the intervention prevents the
appearance of symptoms (that is, slows or arrests the progression of the
disease).”
curehd.blogspot.com/2011/11/waiting-in-wings-gene-positive-and.html
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So, as researchers ramp up to clinical trials, this challenge is gaining
greater attention. At the World Congress on Huntington’s Disease in
Melbourne, Australia, in early September, several scientists revealed their
research into areas directly related to this challenge, including a study of
brain changes in the pre-manifest, the development of measurements from
MRI brain scans to predict and track symptoms, and a report on how
functional MRI scans can detect brain activity changes before brain
shrinkage occurs. (For details click here.)
In his remarks at the World Congress, Blumenstein pointed out that
researchers need both gene-positive and affected individuals to participate
in research studies now in order to prepare adequate measurement tools
for clinical trials.
“It would be a shame if we have potential drugs to test but lack the tools to
conduct the tests to see if they are having the desired effect,” Blumenstein
wrote to me.
“What the FDA will accept for regulatory purposes (i.e., to approve a drug)
and whether we can satisfy ourselves that we are on the right track
scientifically to modify the disease are two different questions,” he added.
“We will need people like you to participate in studies and, yes, trials to
establish the latter. When we are successful with that the former may
require some education and lobbying of the regulators to convince them
that new approaches to approving drugs for genetic diseases are
appropriate.”
Waiting in the wings
For the beleaguered Huntington’s disease community, clinical trials of
potential treatments provide a ray of hope.
Looking back to my mother’s diagnosis in 1995, I recognize that
researchers have made stunning progress. But big hurdles remain,
especially in developing preventive treatments for the pre-manifest.
I share the researchers’ optimism, but I temper it with a sober assessment
of the complexity of the challenges.
For me, time is ever more precious.
Once again, it’s crystal clear that researchers ultimately rely on the
participation of HD-affected families. Everybody can play a part – the
untested at risk and the pre-manifest in research studies, and the affected
in clinical trials.
The affected will bravely pioneer treatments by initiating the trials.
For the time being, however, gene-positive individuals like me must wait
in the wings.
But we can assist immensely by supporting the affected, advocating for the
cause, and, perhaps most importantly, taking part in the appropriate
studies and experiments.
Together we dream of the day when we can all declare: “I’m HD-free!”
Today, being gene-positive for Huntington’s disease threatens the wellbeing of me and my family. But if the science continues to accelerate, it will
provide hope that carrying the HD gene will become little more than an
inconvenience.
Posted by Gene Veritas at 9:51 PM
Labels: asymptomatic , brain , caregiver , CHDI , clinical trial , coenzyme Q-10 ,
Enroll-HD , FDA , gene-positive , genetic test , Huntington's , onset , pre-manifest ,
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2 comments:
Sean Thompson, PREDICT-HD Public Relations
Coordinator said...
Hi Gene,
Great post; I admire the honesty with which you write. This is
the kind of feedback that we on the research side need to hear
from people in the HD community. The desire of people such as
yourself who don't exhibit the clinical signs of HD to take part
in clinical trials would be well received by researchers and
reinforces what we're trying to discover in PREDICT-HD. This
observational trial for people not showing clinical signs of HD
is attempting to identify the earliest signs of HD to learn more
about the progression of the disease, identify areas that can be
targeted with treatments to slow or prevent onset before
people's health starts to be affected, and validate measures that
can be used in the very clinical trials for people not showing
clinical signs of HD that you speak of.
Your dedication to doing whatever you can to contribute to HD
research and fight against this disease shines through in the
fact that you aren't lamenting the fact that you're being asked to
participate in too many research trials and studies, rather, not
enough clinical trials. The desire of yourself and others who
want to do more (and we hear it often) is what is going to help
researchers meet enrollment goals for clinical trials and
observational studies. And difficulty meeting those goals is
often what holds research up the most.
Thanks again for the post, and keep sharing your thoughts!
8:31 AM, December 01, 2011

Beverly said...
Hi Gene:
I've been busy with teaching duties at end of my semester, so I
got behind in reading your blog. You know all about that. I just
caught up and read several blogs at once. I want you to know
how much I depend on you to share not just ideas and
information, but also your emotional responses to what's going
on. I'm the support person for someone in the early stages of
being symptomatic, and your blog sometimes opens up ways
for us to discuss HD.
I feel guilty telling you that because of your encouragement to
participate in clinical trials, my fiance was able to participate in
the trial of ACR-16. When I thanked you for that
curehd.blogspot.com/2011/11/waiting-in-wings-gene-positive-and.html
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encouragement before, I did not realize that you were not
eligible to be in such trials.
I'm sorry if I rubbed salt in the wound.
Funny story: the doctors and I thought he did really well in the
double-blind part of the trial. Guess what he was on? Placebo!
8:37 AM, December 05, 2011
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